Inclusion:
	‚Ä¢ Women aged ‚â•18 years.
	‚Ä¢ Diagnosed with FIGO stage IIIC‚ÄìIV epithelial ovarian, fallopian tube, or primary peritoneal cancer.
	‚Ä¢ Underwent primary debulking surgery (PDS) followed by platinum-based chemotherapy.
	‚Ä¢ Histology types included: serous, endometrioid, mucinous, and clear cell.
Exclusion:
	‚Ä¢ Received neoadjuvant chemotherapy followed by interval debulking surgery (IDS).
	‚Ä¢ Had PDS without subsequent chemotherapy.
	‚Ä¢ Received chemotherapy alone or no treatment.
	‚Ä¢ Patients with chemotherapy start dates >90 days after surgery were excluded due to suspected registration bias.
üìå So no, patients who received neoadjuvant therapy were not included.

Inclusion Criteria
	‚Ä¢ Stage IIIB‚ÄìIVB EOC
	‚Ä¢ Underwent primary cytoreductive surgery
	‚Ä¢ Received postoperative chemotherapy
	‚Ä¢ Known TTC interval
Exclusion Criteria
	‚Ä¢ Low malignant potential tumors (n=15)
	‚Ä¢ Neoadjuvant chemotherapy (n=14)
	‚Ä¢ Refused chemotherapy (n=2)
	‚Ä¢ Died before chemotherapy (n=4)
	‚Ä¢ Lost to follow-up or relocated (n=3)
	‚Ä¢ Missing TTC data (n=5)

Inclusion / Exclusion Criteria
Included	Excluded
EOC (any FIGO stage)	Neoadjuvant chemotherapy
Primary complete macroscopic CRS	Borderline/non-epithelial tumors
Platinum-based adjuvant chemo (6 cycles)	Incomplete resection (residual tumor)

üë• Inclusion/Exclusion Criteria
	‚Ä¢ Inclusion:
		‚óã Primary epithelial ovarian cancer
		‚óã FIGO stage IIIC or IV
		‚óã Surgery performed at Mayo Clinic
		‚óã Received postoperative chemotherapy
	‚Ä¢ Exclusion:
		‚óã Prior chemotherapy
		‚óã Surgery at outside institutions
		‚óã Missing chemotherapy data
		‚óã No chemotherapy due to death or performance status (13 patients)

Inclusion Criteria
	‚Ä¢ Women in Denmark who:
		‚óã Underwent primary surgery for epithelial ovarian cancer (OC) between January 1, 2005 and December 31, 2006
		‚óã Had documented initiation of adjuvant chemotherapy
		‚óã Were registered in the Danish Gynaecological Cancer Database (DGCD)

Exclusion Criteria
Patients were excluded for the following reasons:
	1. Age < 18 years (n = 4)
	2. No surgery performed (n = 1)
	3. No chemotherapy administered (n = 473), reasons included:
		‚óã Low-stage OC (n = 57)
		‚óã Borderline tumor (n = 261)
		‚óã Sex-cord stromal cancer (n = 14)
		‚óã Germ cell tumor (n = 3)
		‚óã Poor general condition, high age, death, or patient refusal (n = 100)
		‚óã Other cancer types (n = 17)
		‚óã Unknown reasons (n = 21)
	4. Missing data on chemotherapy administration (n = 12)
	5. Neoadjuvant chemotherapy (i.e., chemotherapy before surgery) (n = 69)
	6. Chemotherapy initiated >100 days after surgery (n = 14)
		‚óã These were excluded because delays were typically due to special clinical reasons, such as severe complications or patient refusal

‚úÖ Inclusion Criteria
	‚Ä¢ Stage IA/IB (grade 3), IC, II, or any Stage I/II clear cell carcinoma
	‚Ä¢ Surgery performed per GOG protocol by gynecologic oncologists
	‚Ä¢ Randomized to adjuvant chemotherapy per protocol
	‚Ä¢ Complete follow-up and timing data

‚ùå Exclusion Criteria
	‚Ä¢ Missing or incomplete data on surgery or chemotherapy start dates
	‚Ä¢ Patients not meeting GOG protocol eligibility (e.g., wrong histology or stage)

